Nile

Empowering Patients to Advance Precision Medicine, One EHR at a Time

Electronic health record (EHR) systems store incredibly rich data about individual patients, but historically, individuals have been unable to access this information easily and share it for research. However, use of patients’ data could accelerate scientific discovery and progress toward precision medicine. Permitting patients to… Read More »Empowering Patients to Advance Precision Medicine, One EHR at a Time

Emergent Warfarin Reversal With Fixed-Dose 4-Factor Prothrombin Complex Concentrate

Annals of Pharmacotherapy, Ahead of Print. Background: Four-factor prothrombin complex concentrate (4FPCC) is used for emergent warfarin reversal, but dosing remains controversial. Following approval, further studies have evaluated a variety of fixed-dose regimens. The studies utilized lower doses as compared with package insert dosing and… Read More »Emergent Warfarin Reversal With Fixed-Dose 4-Factor Prothrombin Complex Concentrate

Emergent Warfarin Reversal With Fixed-Dose 4-Factor Prothrombin Complex Concentrate

Annals of Pharmacotherapy, Ahead of Print. Background: Four-factor prothrombin complex concentrate (4FPCC) is used for emergent warfarin reversal, but dosing remains controversial. Following approval, further studies have evaluated a variety of fixed-dose regimens. The studies utilized lower doses as compared with package insert dosing and… Read More »Emergent Warfarin Reversal With Fixed-Dose 4-Factor Prothrombin Complex Concentrate

Emergent Warfarin Reversal With Fixed-Dose 4-Factor Prothrombin Complex Concentrate

Annals of Pharmacotherapy, Ahead of Print. Background: Four-factor prothrombin complex concentrate (4FPCC) is used for emergent warfarin reversal, but dosing remains controversial. Following approval, further studies have evaluated a variety of fixed-dose regimens. The studies utilized lower doses as compared with package insert dosing and… Read More »Emergent Warfarin Reversal With Fixed-Dose 4-Factor Prothrombin Complex Concentrate

Clearance Confusion: An Exploratory Analysis of Inpatient Dosing Discordances Between Renal Estimating Equations

Annals of Pharmacotherapy, Ahead of Print. Background: Numerous equations exist for estimating renal clearance for drug dosing, and discordance rates may be as high as 40% in certain populations. However, the populations and types of equations used in these studies may not be generalizable to… Read More »Clearance Confusion: An Exploratory Analysis of Inpatient Dosing Discordances Between Renal Estimating Equations

Clearance Confusion: An Exploratory Analysis of Inpatient Dosing Discordances Between Renal Estimating Equations

Annals of Pharmacotherapy, Ahead of Print. Background: Numerous equations exist for estimating renal clearance for drug dosing, and discordance rates may be as high as 40% in certain populations. However, the populations and types of equations used in these studies may not be generalizable to… Read More »Clearance Confusion: An Exploratory Analysis of Inpatient Dosing Discordances Between Renal Estimating Equations

Clearance Confusion: An Exploratory Analysis of Inpatient Dosing Discordances Between Renal Estimating Equations

Annals of Pharmacotherapy, Ahead of Print. Background: Numerous equations exist for estimating renal clearance for drug dosing, and discordance rates may be as high as 40% in certain populations. However, the populations and types of equations used in these studies may not be generalizable to… Read More »Clearance Confusion: An Exploratory Analysis of Inpatient Dosing Discordances Between Renal Estimating Equations

Anticoagulation Management for Impella Percutaneous Ventricular Assist Devices: An Analysis of a Single-Center Experience

Annals of Pharmacotherapy, Ahead of Print. Background: Impella devices offer temporary mechanical circulatory support for cardiogenic shock. The manufacturer recommends systemic anticoagulation with a target activated clotting time of 160 to 180 s but provides no guidance on how to manage both the heparinized purge… Read More »Anticoagulation Management for Impella Percutaneous Ventricular Assist Devices: An Analysis of a Single-Center Experience

Anticoagulation Management for Impella Percutaneous Ventricular Assist Devices: An Analysis of a Single-Center Experience

Annals of Pharmacotherapy, Ahead of Print. Background: Impella devices offer temporary mechanical circulatory support for cardiogenic shock. The manufacturer recommends systemic anticoagulation with a target activated clotting time of 160 to 180 s but provides no guidance on how to manage both the heparinized purge… Read More »Anticoagulation Management for Impella Percutaneous Ventricular Assist Devices: An Analysis of a Single-Center Experience

Anticoagulation Management for Impella Percutaneous Ventricular Assist Devices: An Analysis of a Single-Center Experience

Annals of Pharmacotherapy, Ahead of Print. Background: Impella devices offer temporary mechanical circulatory support for cardiogenic shock. The manufacturer recommends systemic anticoagulation with a target activated clotting time of 160 to 180 s but provides no guidance on how to manage both the heparinized purge… Read More »Anticoagulation Management for Impella Percutaneous Ventricular Assist Devices: An Analysis of a Single-Center Experience

Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment

Annals of Pharmacotherapy, Ahead of Print. Background: Response-guided hepatitis C therapy was standard with interferon-based regimens but is not used for direct-acting antivirals (DAAs). Week 4 viral kinetics may predict sustained virological response (SVR) with DAAs, but it is unclear whether extending therapy in slow… Read More »Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment

Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment

Annals of Pharmacotherapy, Ahead of Print. Background: Response-guided hepatitis C therapy was standard with interferon-based regimens but is not used for direct-acting antivirals (DAAs). Week 4 viral kinetics may predict sustained virological response (SVR) with DAAs, but it is unclear whether extending therapy in slow… Read More »Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment

Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment

Annals of Pharmacotherapy, Ahead of Print. Background: Response-guided hepatitis C therapy was standard with interferon-based regimens but is not used for direct-acting antivirals (DAAs). Week 4 viral kinetics may predict sustained virological response (SVR) with DAAs, but it is unclear whether extending therapy in slow… Read More »Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment

Incidence and Risk Factors of Acute Kidney Injury in Patients Receiving Concomitant Vancomycin and Continuous-Infusion Piperacillin/Tazobactam: A Retrospective Cohort Study

Annals of Pharmacotherapy, Ahead of Print. Background: During a recent shortage of small-volume parenteral solutions, some hospitals administered piperacillin/tazobactam via continuous infusion to utilize larger fluid volumes. Although the incidence of acute kidney injury (AKI) is well documented for patients receiving intermittent or extended-infusion piperacillin/tazobactam… Read More »Incidence and Risk Factors of Acute Kidney Injury in Patients Receiving Concomitant Vancomycin and Continuous-Infusion Piperacillin/Tazobactam: A Retrospective Cohort Study

Incidence and Risk Factors of Acute Kidney Injury in Patients Receiving Concomitant Vancomycin and Continuous-Infusion Piperacillin/Tazobactam: A Retrospective Cohort Study

Annals of Pharmacotherapy, Ahead of Print. Background: During a recent shortage of small-volume parenteral solutions, some hospitals administered piperacillin/tazobactam via continuous infusion to utilize larger fluid volumes. Although the incidence of acute kidney injury (AKI) is well documented for patients receiving intermittent or extended-infusion piperacillin/tazobactam… Read More »Incidence and Risk Factors of Acute Kidney Injury in Patients Receiving Concomitant Vancomycin and Continuous-Infusion Piperacillin/Tazobactam: A Retrospective Cohort Study

Incidence and Risk Factors of Acute Kidney Injury in Patients Receiving Concomitant Vancomycin and Continuous-Infusion Piperacillin/Tazobactam: A Retrospective Cohort Study

Annals of Pharmacotherapy, Ahead of Print. Background: During a recent shortage of small-volume parenteral solutions, some hospitals administered piperacillin/tazobactam via continuous infusion to utilize larger fluid volumes. Although the incidence of acute kidney injury (AKI) is well documented for patients receiving intermittent or extended-infusion piperacillin/tazobactam… Read More »Incidence and Risk Factors of Acute Kidney Injury in Patients Receiving Concomitant Vancomycin and Continuous-Infusion Piperacillin/Tazobactam: A Retrospective Cohort Study

Thank You, Nurses

Follow along with our new blog series #HealthcareNow and #PublicSectorNow, where we’ll addresses healthcare innovation around the world and how to maintain business continuity in today’s health climate.  Today is International Nurses Day, a day to celebrate nurses and the huge impact they have on the lives of… Read More »Thank You, Nurses

Announcing the Spring Issue of THE EVIDENCE FORUM: A Focus on Digital Technologies

Access the issue now https://bit.ly/evidera052020 Evidera’s biannual publication focused on the scientific, strategic, and operational challenges of today’s healthcare environment. This issue highlights a variety of topics to address our industry’s most pressing issues, such as working in the era of COVID-19, continuing to engage patients… Read More »Announcing the Spring Issue of THE EVIDENCE FORUM: A Focus on Digital Technologies

Want to start a business in the ePharmacy industry?

The growth of the Global ePharmacy market valued approximately USD 42.32 billion in 2019, and it is anticipated to grow USD 107.53 by 2024. Let us understand this ePharmacy industry a little more…. https://medium.com/@kodyTechnolab/how-to-start-online-medicine-delivery-business-ideal-5f5ec7eba354 submitted by /u/KodyTechnolab [link] [comments]

Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19

Annals of Pharmacotherapy, Volume 54, Issue 8, Page 827-831, August 2020. The world is suffering a respiratory pandemic disease caused by a novel coronavirus (2019-nCoV), commonly known as COVID-19 (coronavirus disease 2019). The Food and Drug Administration issued an emergency authorization for chloroquine and hydroxychloroquine… Read More »Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19

ESENER 2019 reveals biggest concerns for European workplaces – musculoskeletal disorders and psychosocial risks

08/05/2020 – 01:45 ESENER 2019 reveals biggest concerns for European workplaces – musculoskeletal disorders and psychosocial risks The European Agency for Safety and Health at Work (EU-OSHA) launches the results of its 2019 European Survey of Enterprises on New and Emerging Risks (ESENER) on the… Read More »ESENER 2019 reveals biggest concerns for European workplaces – musculoskeletal disorders and psychosocial risks

Does Aspartame Cause Lymphoma?

The approval of aspartame has a controversial history. The Commissioner of the U.S. Food and Drug Administration (FDA) concluded that “there is a reasonable certainty that human consumption of aspartame: (1) …will not pose a risk of brain damage resulting in mental retardation, endocrine [hormonal]… Read More »Does Aspartame Cause Lymphoma?

NURSES’ PERCEPTION OF MOTIVATION AND JOB SATISFACTION IN GHANA: A CASE STUDY OF THE KORLE-BU TEACHING HOSPITAL IN ACCRA

AUTHORS :1Charles Owusu-Aduomi Botchwey*, 2Yaa Kusi-Ameyaa, 1Isaac Adom-Konadu,  1Ebenezer Dzinpa Effisah1 University of Cape Coast2 University of Professional Studies-Accra chaboat08@yahoo.com* ABSTRACT Healthcare provision aims at ensuring that clients who visit a healthcare facility are provided with affordable and quality healthcare aimed at promoting the well-being… Read More »NURSES’ PERCEPTION OF MOTIVATION AND JOB SATISFACTION IN GHANA: A CASE STUDY OF THE KORLE-BU TEACHING HOSPITAL IN ACCRA

Healthcare Success hires new senior executive to lead creative development and execution

The Healthcare-Focused Marketing Firm Welcomes Executive Creative Director Dana Callow IRVINE, Calif., April 24, 2020 – Adding to the recent expansion of its leadership team, full-service healthcare marketing and advertising agency Healthcare Success is proud to announce the hiring of Executive Creative Director Dana Callow.… Read More »Healthcare Success hires new senior executive to lead creative development and execution

Addiction Treatment Center Marketing Webinar: How to Adjust Now and After COVID

 We have never seen an addiction treatment marketing landscape as the one that continues to evolve due to COVID-19. Stewart Gandolf, CEO, Healthcare Success Kathy Gaughran, Senior Healthcare Marketing Strategist, Healthcare Success While some substance abuse and behavioral health centers are withdrawing from marketing,… Read More »Addiction Treatment Center Marketing Webinar: How to Adjust Now and After COVID

Opioid Prescribing After Discharge in a Previously Mechanically Ventilated, Opioid-Naïve Cohort

  • by

Annals of Pharmacotherapy, Ahead of Print. Background: Opioids are utilized for pain management during and after mechanical ventilation in the intensive care unit (ICU). Objective: The purpose of this study was to determine the percentage of potentially unnecessary opioid prescriptions on discharge in previously opioid-naïve… Read More »Opioid Prescribing After Discharge in a Previously Mechanically Ventilated, Opioid-Naïve Cohort

Opioid Prescribing After Discharge in a Previously Mechanically Ventilated, Opioid-Naïve Cohort

  • by

Annals of Pharmacotherapy, Ahead of Print. Background: Opioids are utilized for pain management during and after mechanical ventilation in the intensive care unit (ICU). Objective: The purpose of this study was to determine the percentage of potentially unnecessary opioid prescriptions on discharge in previously opioid-naïve… Read More »Opioid Prescribing After Discharge in a Previously Mechanically Ventilated, Opioid-Naïve Cohort

Opioid Prescribing After Discharge in a Previously Mechanically Ventilated, Opioid-Naïve Cohort

  • by

Annals of Pharmacotherapy, Ahead of Print. Background: Opioids are utilized for pain management during and after mechanical ventilation in the intensive care unit (ICU). Objective: The purpose of this study was to determine the percentage of potentially unnecessary opioid prescriptions on discharge in previously opioid-naïve… Read More »Opioid Prescribing After Discharge in a Previously Mechanically Ventilated, Opioid-Naïve Cohort

Medication Regimen Complexity Index Prediction of Adverse Drug Reaction–Related Hospital Admissions

  • by

Annals of Pharmacotherapy, Volume 54, Issue 10, Page 996-1000, October 2020. Background:The relationship between the medication regimen complexity index (MRCI) and adverse drug reaction (ADR)-related hospital admissions has not yet specifically been investigated.Objective:To evaluate the MRCI and compare with medication count for prediction of ADR-related… Read More »Medication Regimen Complexity Index Prediction of Adverse Drug Reaction–Related Hospital Admissions

Medication Regimen Complexity Index Prediction of Adverse Drug Reaction–Related Hospital Admissions

  • by

Annals of Pharmacotherapy, Ahead of Print. Background: The relationship between the medication regimen complexity index (MRCI) and adverse drug reaction (ADR)-related hospital admissions has not yet specifically been investigated. Objective: To evaluate the MRCI and compare with medication count for prediction of ADR-related hospital admissions… Read More »Medication Regimen Complexity Index Prediction of Adverse Drug Reaction–Related Hospital Admissions

Medication Regimen Complexity Index Prediction of Adverse Drug Reaction–Related Hospital Admissions

  • by

Annals of Pharmacotherapy, Ahead of Print. Background: The relationship between the medication regimen complexity index (MRCI) and adverse drug reaction (ADR)-related hospital admissions has not yet specifically been investigated. Objective: To evaluate the MRCI and compare with medication count for prediction of ADR-related hospital admissions… Read More »Medication Regimen Complexity Index Prediction of Adverse Drug Reaction–Related Hospital Admissions

Scaling Virtual Consultations

  • by

Follow along with our new blog series #HealthcareNow and #PublicSectorNow, where we’ll addresses healthcare innovation around the world and how to maintain business continuity in today’s health climate.  The healthcare landscape is quickly changing and we’re entering a new era of patient-centered care delivery –… Read More »Scaling Virtual Consultations

The Benefits of Slow Breathing

  • by

There are all manner of purported hiccup “cures,” which include everything from chewing on a lemon, inhaling pepper, or, our dog’s favorite, eating a spoonful of peanut butter. In my video How to Strengthen the Mind-Body Connection, I talk about the technique I’m excited to… Read More »The Benefits of Slow Breathing

Disparities in the Use of Guideline-Based Pharmacotherapy Exist for Atherosclerotic Cardiovascular Disease and Heart Failure Patients Who Have Intellectual/Developmental Disabilities in a Commercially Insured Database

  • by

Annals of Pharmacotherapy, Volume 54, Issue 10, Page 958-966, October 2020. Background:Patients who have intellectual/developmental disabilities (IDDs) develop atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF) at rates similar to or higher than the general population. They also face disparities accessing and using health care… Read More »Disparities in the Use of Guideline-Based Pharmacotherapy Exist for Atherosclerotic Cardiovascular Disease and Heart Failure Patients Who Have Intellectual/Developmental Disabilities in a Commercially Insured Database

Disparities in the Use of Guideline-Based Pharmacotherapy Exist for Atherosclerotic Cardiovascular Disease and Heart Failure Patients Who Have Intellectual/Developmental Disabilities in a Commercially Insured Database

  • by

Annals of Pharmacotherapy, Ahead of Print. Background: Patients who have intellectual/developmental disabilities (IDDs) develop atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF) at rates similar to or higher than the general population. They also face disparities accessing and using health care services. Objective: To determine… Read More »Disparities in the Use of Guideline-Based Pharmacotherapy Exist for Atherosclerotic Cardiovascular Disease and Heart Failure Patients Who Have Intellectual/Developmental Disabilities in a Commercially Insured Database

Disparities in the Use of Guideline-Based Pharmacotherapy Exist for Atherosclerotic Cardiovascular Disease and Heart Failure Patients Who Have Intellectual/Developmental Disabilities in a Commercially Insured Database

  • by

Annals of Pharmacotherapy, Ahead of Print. Background: Patients who have intellectual/developmental disabilities (IDDs) develop atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF) at rates similar to or higher than the general population. They also face disparities accessing and using health care services. Objective: To determine… Read More »Disparities in the Use of Guideline-Based Pharmacotherapy Exist for Atherosclerotic Cardiovascular Disease and Heart Failure Patients Who Have Intellectual/Developmental Disabilities in a Commercially Insured Database